ALX Oncology Holdings Inc. Files 8-K with Board and Compensation Changes
Ticker: ALXO · Form: 8-K · Filed: Jan 22, 2025 · CIK: 1810182
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
Related Tickers: ALXO
TL;DR
ALXO 8-K: Board shakeup and comp changes filed Jan 16.
AI Summary
ALX Oncology Holdings Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. The filing also includes a Regulation FD disclosure and other events, along with financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about the company's direction and stability.
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- January 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 323 Allerton Avenue, South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates a "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" but does not detail the specific changes within this summary.
What are the key aspects of the compensatory arrangements mentioned?
The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the specific details of these arrangements are not provided in the summary.
What is the significance of the Regulation FD Disclosure?
A Regulation FD Disclosure is included, which means the company is making material non-public information available to all investors simultaneously.
When was the report filed and what is the earliest event date?
The report was filed as of January 22, 2025, with the earliest event reported on January 16, 2025.
What is the primary business of ALX Oncology Holdings Inc. according to the filing?
ALX Oncology Holdings Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Filing Stats: 2,066 words · 8 min read · ~7 pages · Grade level 9.7 · Accepted 2025-01-22 08:01:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
- $490,000 — Shantharam's annual base salary will be $490,000, less any applicable withholdings. Mr.
Filing Documents
- alxo-20250116.htm (8-K) — 75KB
- alxo-ex99_1.htm (EX-99.1) — 22KB
- img62044099_0.jpg (GRAPHIC) — 17KB
- 0000950170-25-007532.txt ( ) — 242KB
- alxo-20250116.xsd (EX-101.SCH) — 25KB
- alxo-20250116_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer Effective January 21, 2025, the Board of Directors (the "Board") of ALX Oncology Holdings Inc. (the "Company") appointed Harish Shantharam to the office of Chief Financial Officer to replace Shelly Pinto, who was serving as the Company's Interim Chief Financial Officer. In the role of Chief Financial Officer, Mr. Shantharam will serve as the Company's principal financial officer. Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company's Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer. Harish Shantharam, age 44, served as the Chief Financial Officer of CymaBay Therapeutics, Inc., a public pharmaceutical company, from May 2023 to June 2024, including through the completion of its acquisition in March 2024 by Gilead Sciences, a public pharmaceutical company. Prior to that, he served as Senior Finance Consultant at Eikon Therapeutics, a biopharmaceutical company, from August 2022 to April 2023, where he worked with the Chief Financial Officer in supporting finance operations. He was employed at Gilead from October 2011 through May 2022, where he held various positions within the finance function, most recently that of Vice President, Head of Global Commercial Finance. At Gilead, Mr. Shantharam was responsible for managing Gilead's global commercial financial operations. Prior to Gilead, Mr. Shantharam held multiple roles in commercial planning and operations at Amgen Inc., a pharmaceutical company, from February 2004. Mr. Shantharam received his M.B.A. from UCLA Anderson School of Management and is a CFA charterholder. There are no arrangements or understandings between Mr. Shantharam and any other persons pursuant to which he was appointed Chief Financial Offi
01
Item 7.01 Regulation FD Disclosure. On January 22, 2025, the Company issued a press release announcing the appointment of Mr. Shantharam as Chief Financial Officer of the Company and the appointments of Dr. Klencke and Dr. Takimoto to its Board. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including the related information set forth in the press release attached hereto as Exhibit 99.1, is being "furnished" and shall not be deemed "filed" with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. 2
01
Item 8.01 Other Events. In connection with the Board changes referenced above, the Board approved the following composition of committees of the Board: Audit Committee Rekha Hemrajani, Chair; Scott Garland; and Barbara Klencke, M.D. Compensation Committee Corey Goodman, Ph.D., Chair; Scott Garland; and Chris Takimoto, M.D., Ph.D., F.A.C.P. Corporate Governance and Nominating Committee Scott Garland, Chair; Corey Goodman, Ph.D.; and Rekha Hemrajani Research and Development Committee Corey Goodman, Ph.D., Chair; Barbara Klencke, M.D.; and Chris Takimoto, M.D., Ph.D., F.A.C.P.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated January 22, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALX ONCOLOGY HOLDINGS INC. Date: January 22, 2025 By: /s/ Jason Lettmann Jason Lettmann Chief Executive Officer 4